NPCE

Over the past six months, NeuroPace's stock has experienced several notable events. The company reported its fourth quarter and full year 2025 financial results in early March 2026, and is scheduled to report its first quarter 2026 financial results on May 12, 2026. In January 2026, NeuroPace reported preliminary unaudited results for Q4 and FY 2025, with total revenue of approximately $26.6 million for Q4 2025 and $100 million for FY 2025. NeuroPace highlighted expanding clinical evidence leadership with published 3-year Post-Approval Study (PAS) results and a NAUTILUS Presentation at AAN 2026 in April 2026. A Premarket Approval Supplement (PMA-S) for an expanded IGE indication was filed in December 2025, with an FDA decision expected around June 15, 2026. NeuroPace presented at the Leerink Global Healthcare Conference in March 2026 and the 25th Annual Needham Virtual Healthcare Conference in April 2026. In April 2025, the company announced it would terminate its distribution relationship for SEEG products to focus on its core RNS System. The stock has gained 59.2% over the past 12 months and hit a new 52-week high in May 2026. Analysts have a "Moderate Buy" consensus rating with an average target price of $18.67.